CDKN1A and chronic myelogenous leukemia, BCR-ABL1 positive: After treatment of the imatinib mesylate (IM)-sensitive CML cell line KCL22S with Dasatinib or Nilotinib, a restoration of KMT2C gene expression and a higher rate of apoptosis and enhanced expression of p21 (CDKN1A) compared to the control group was observed, accompanied by a decrease in the expression of CDK2, CDK4, and Cyclin B1 (CCNB1), which suggests that the p53 regulatory pathway is involved in the regulation of cancer by KMT2C (49).